Compare NXRT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 696.3M | 1.2B |
| IPO Year | 2014 | 2015 |
| Metric | NXRT | COLL |
|---|---|---|
| Price | $24.61 | $36.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $31.00 | ★ $50.83 |
| AVG Volume (30 Days) | 201.9K | ★ 430.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | $251,281,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $3.81 | $5.93 |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | $20.12 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $25.26 | $23.23 |
| 52 Week High | $40.78 | $50.79 |
| Indicator | NXRT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 27.26 | 34.67 |
| Support Level | N/A | $34.29 |
| Resistance Level | $32.12 | $39.85 |
| Average True Range (ATR) | 0.89 | 1.31 |
| MACD | -0.23 | -0.12 |
| Stochastic Oscillator | 0.23 | 27.86 |
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.